Qiming Venture Partners

Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. Qiming currently manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management, and strives to be the investor of choice for top entrepreneurs in China. Qiming healthcare team has been one of most active investors in China and many of their healthcare portfolio companies are today's most influential brands in the healthcare sector. For more information, please visit


Northern Light Venture Capital

Northern Light Venture Capital (NLVC) is a leading China-focused venture capital firm targeting early stage opportunities of innovation and disruptive technology. With over US$1.7 billion capital under management, Northern Light has backed over 180 ventures in TMT, healthcare and advanced technology since its inception in 2005. Leveraging significant investing and entrepreneurial expertise in both China and the United States, the NLVC team looks to support entrepreneurs with groundbreaking ideas and exceptional vision to develop lasting ventures that positively impact society. For more information, please visit:


Kaifeng Venture Capital

Since its inception in 2009, Kaifeng Venture Capital has been focused on the early investment in science and technology enterprises, mainly related to TMT and Bio Medical field. At present, there are funds or branches in Beijing, Shanghai, Suzhou, Nanjing, Hongkong and Shenzhen. They have managed five RMB funds and a US dollar fund totaling about 3 billion yuan. Kaifeng has invested in about 50 outstanding enterprises in the medical field, such as innovative drug development, high-end medical equipment, medical service and Internet plus, and some of them has become star projects. For more information, please visit the venture's official website:

Lapam Capital

Headquartered in Beijing, Lapam Capital is a leading healthcare-focused venture capital firm in China, with over RMB 2 billion capital under management. Lapam Capital targets both early stage and fast growing opportunities, and has built a strong investment portfolio with innovative and disruptive healthcare technology. Lapam Capital has already invested in dozens of Chinese pharmaceutical companies, which together have generated nearly half of all Class I new small molecule drugs marketed by privately-held companies in China. Lapam Capital provides comprehensive value-added services tailored for healthcare portfolio.

Anlong fund

Anlong fund founded in 2015 is an investment fund at early stage controlled by Chinese academy of sciences holdings company and OSCI holdings group company. The fund owns resourceful projects, value-added services and exits returns. Dr. Chun-lin Zhao is the management partner with rich experiences for 30 years, and led a professional investment team which possesses abundant experiences in multinational companies, domestic and foreign research and development clinical and successful experience of entrepreneurship.

Fund fundamental investors is Chinese academy of sciences, and have a first scale of 300 million RMB, second scale of 800 million. “If you have not seen Anlong fund, that you haven't seen the professional investors in life science!” Anlong fund focuses on domestic early stage in the field of life science and medical health field, and owns extensive experience and deep contacts in Chinese academy of sciences, Tsinghua university, Peking union medical college and the BayHelix group. Anlong fund has powerful resource and is a good helper of entrepreneurs in life science and medical health field. In the past two years, with the unique insights of investment team, Anlong fund move fast in the areas of medicine, medical apparatus and instruments, including three co-founded enterprises and 21 invested companies, more than doubled after the valuation. Anlong fund has always been adhering to the philosophy is “evolving excellent people, doing better”. This also is the core experience in the field of healthcare over these years.

Please visit:

TEL/FAX: 0512-53577866


ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower